KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Other financing activities (2021 - 2024)

Ginkgo Bioworks Holdings' Other financing activities history spans 4 years, with the latest figure at $4000.0 for Q4 2024.

  • For Q4 2024, Other financing activities fell 99.66% year-over-year to $4000.0; the TTM value through Dec 2025 reached $1.2 million, changed 0.08%, while the annual FY2023 figure was $580000.0, N/A changed from the prior year.
  • Other financing activities reached $4000.0 in Q4 2024 per DNA's latest filing, up from -$4000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $59.8 million in Q3 2021 to a low of -$25.7 million in Q2 2021.
  • Average Other financing activities over 4 years is $6.2 million, with a median of $1500.0 recorded in 2023.
  • Peak YoY movement for Other financing activities: surged 1582.09% in 2022, then crashed 300.0% in 2024.
  • A 4-year view of Other financing activities shows it stood at -$67000.0 in 2021, then soared by 1582.09% to $993000.0 in 2022, then rose by 19.23% to $1.2 million in 2023, then plummeted by 99.66% to $4000.0 in 2024.
  • Per Business Quant, the three most recent readings for DNA's Other financing activities are $4000.0 (Q4 2024), -$4000.0 (Q3 2024), and $1.2 million (Q4 2023).